Sophia Genetics reaches milestone to become the global leader in precision medicine

Sophia Genetics has risen to become the global leader in precision medicine, connecting over 100 hospitals and laboratories to form the world’s largest clinical genomics community for Molecular Diagnosis. Witnessing a 400% growth rate this year alone, it has supported the diagnosis of over 25,000 patients in Europe and 80,000 patients are expected to benefit in 2016. The platform is rising to become the largest network globally for sharing knowledge and interpreting clinical genomics data.

All 100 plus institutions within the community use Sophia Genetics’ cutting edge analytical solution and its advanced machine learning algorithms to analyse the genetic make-up of some common cancers and inherited conditions, such as such as cystic fibrosis, so that clinicians can more accurately diagnose patients at speed and at scale.

Speaking about this key milestone moment, Jurgi Camblong, CEO and co-founder of Sophia Genetics commented: “Over the past 18 months, Sophia Genetics’ technology has been able to make precision medicine a reality for healthcare institutions across Europe, helping patients benefit from faster and more accurate diagnosis. I am thrilled that Sophia Genetics today has been recognised as the global leader in this field, and is helping Europe lead the wider healthcare industry in delivering the value and promises associated with personalised medicine.”

Within the UK, Oxford University Hospital, Newcastle Medical Genetics, Aberdeen Medical Genetics, Liverpool Women’s NHS Foundation Trust and NewGene leverage Sophia Genetics’ industry-leading genetic analysis technology to provide clinicians the most accurate, fast and cost-effective means to offer genomic analysis of samples to their patients.

Since its inception, Sophia has built an innovative network of pioneer healthcare institutions. The community now spans 18 European countries from Spain to Poland, and places Europe as a leader in precision medicine. More countries are expected to join as new hospitals and labs make use of Sophia DDM.

(Press release)